Does New CF Approvals And IgAN Filing Change The Bull Case For Vertex Pharmaceuticals (VRTX)?

Vertex Pharmaceuticals recently received expanded U.S. FDA approvals for its cystic fibrosis therapies and completed a Biologics License Application for povetacicept for immunoglobulin A nephropathy. These developments aim to diversify Vertex’s portfolio beyond its core CF business, but the investment narrative still hinges on the success of these new areas while managing long-term risks in the CF market. Despite promising projections of $16.0 billion revenue by 2029 and a fair value suggesting a 25% upside, analysts remain divided on the company’s ability to achieve these growth targets given R&D needs and pricing pressures.